eribulin mesylate + vinorelbine + capecitabine + carboplatin

This appears to be an experimental or uncommon combination of four cytotoxic anticancer agents: eribulin mesylate, vinorelbine, capecitabine, and carboplatin. Based on the provided search results, specific detailed information regarding this exact four-drug regimen was not found. Information on dosing, clinical experience, and toxicity is derived from studies involving individual components or subsets of these drugs in combination with other agents. * **Eribulin mesylate**: A microtubule inhibitor that disrupts the mitotic spindle, preventing cell division. * **Vinorelbine**: A vinca alkaloid that also targets microtubules. * **Capecitabine**: An oral prodrug converted to 5-fluorouracil, inhibiting DNA synthesis. * **Carboplatin**: A platinum-based agent forming DNA adducts, inhibiting DNA replication and transcription. While the specific combination was not detailed, related combinations were mentioned in the results: * Eribulin plus carboplatin has shown activity in advanced solid malignancies, including complete response in tonsillar cancer and partial responses in prostate cancer. * Eribulin plus gemcitabine showed a notable overall response rate and clinical benefit rate in breast cancer patients. Information on dosing for this specific combination is not available in the results. Dosing mentioned includes eribulin at 1.4 mg/m² (or 1.23 mg/m² eribulin) on days 1 and 8 of a 21-day cycle as a single agent, eribulin at 1.1 mg/m² with carboplatin AUC 6, and eribulin at 0.88 mg/m² on days 1 and 8 with gemcitabine. Based on related combinations, potential toxicities include neutropenia, thrombocytopenia, fatigue, and liver toxicity.